What changed for Interstitial Lung Disease
A plain English summary of what recently moved in the public data Voxsanity tracks for Interstitial Lung Disease. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Late-stage (Phase 3) trials 25 to 26 (+1)
- Trials on record 1,322 to 1,333 (+11)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Interstitial Lung Disease in July 2026. Voxsanity tracks 2 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 71 trials tracked for Interstitial Lung Disease that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05964335 · results posted 26 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05964335) enrolled 165 adults who were divided into four groups: one group received a placebo (a dummy treatment with no active ingredient), and three groups received different doses of an extended-release form of nalbuphine (NAL ER) — 27 mg, 54 mg, or 108 mg. The trial ran for six weeks and was primarily measuring changes in how often participants coughed over a 24-hour period, tracked using a digital cough monitor. The study appeared to be focused on coughing in people with a lung condition called idiopathic pulmonary fi...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03155620 · results posted 14 April 2026
According to the results reported on ClinicalTrials.gov, this trial — known as the NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol — enrolled 1,377 children and young people with advanced solid tumours, non-Hodgkin lymphomas, or histiocytic disorders (a group of rare diseases involving certain immune cells). The trial was a screening study, meaning its main purpose was to test participants' tumours for specific genetic changes that might match them to one of several targeted treatment sub-studies, rather than to directly test a single drug. The reported data...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04195555 · results posted 25 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04195555) enrolled 3 children or adolescents with a type of cancer that had come back or stopped responding to previous treatment. All 3 participants were given the drug ivosidenib. The main thing the trial was designed to measure was how many participants had their tumour shrink or disappear — known as the "objective response rate." None of the 3 participants completed the study. The reported data shows that, for the primary outcome, 0% of participants had their tumour shrink or disappear while on ivosidenib. For the sec...
-
NCT05321082 · results posted 9 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05321082) enrolled 1,178 people across three groups: 393 received a placebo (dummy treatment), 393 received a lower dose of nerandomilast (9 mg), and 392 received a higher dose (18 mg). The trial ran for up to 52 weeks and was primarily measuring changes in lung capacity — specifically a breathing test called forced vital capacity (FVC), which measures how much air a person can breathe out forcefully. This test is commonly used to track lung function in people with fibrosing interstitial lung disease (scarring of the lung...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04071769 · results posted 2 January 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 34 people who had been newly diagnosed with idiopathic pulmonary fibrosis (IPF) — a condition where the lungs gradually become scarred and stiff. The trial was measuring changes in how well the lungs transfer oxygen into the bloodstream, using a specialised type of MRI scan that uses inhaled xenon gas, as well as standard breathing tests. Of the 34 people who started the trial, 21 completed it and 13 did not. The reported data shows that the primary measurement — called the RBC:barrier ratio, which is a score from a...
-
NCT02615938 · results posted 3 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02615938) involved 35 children in total across four groups, studying a medicine called hydroxychloroquine (HCQ) for a rare childhood lung condition. The trial had two main phases: a "start" phase, where some children began on HCQ and others began on a placebo (a dummy treatment with no active ingredient), and a "stop" phase, where some children stopped taking HCQ and others stopped taking a placebo. The primary thing being measured was whether a child's breathing changed meaningfully — defined as a shift of 5% or more in b...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05032066 · results posted 3 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05032066) enrolled 153 people with idiopathic pulmonary fibrosis (IPF) — a condition that causes scarring of the lungs. Participants were split into three groups: one group received a lower once-daily dose of a drug called HZN-825 before switching to a higher twice-daily dose, a second group received the higher twice-daily dose throughout, and a third group received a placebo (dummy treatment) before also switching to the higher twice-daily dose. The trial's main measurement was lung function, specifically something called...
-
NCT05938920 · results posted 2 December 2025
According to the results reported on ClinicalTrials.gov, this trial looked at an investigational medicine called INS018_055, tested in three different doses and schedules — 30 mg once a day, 30 mg twice a day, and 60 mg once a day — compared against a placebo (a dummy treatment with no active ingredient). A total of 71 people took part across the four groups, with numbers starting between 17 and 18 per group. Not everyone finished the study: by the end, 16 people completed the once-daily 30 mg group, 14 the twice-daily 30 mg group, 13 the 60 mg once-daily group, and 16 the placebo group. The t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03422068 · results posted 28 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 15 people in total — 5 received a placebo (a dummy treatment with no active ingredient) and 10 received the study drug, BI 1015550, at an 18 mg dose. All 5 people in the placebo group finished the trial, while 8 out of 10 in the drug group completed it, with 2 not completing. The trial was primarily measuring how often participants experienced unwanted events (called adverse events) that were considered related to the study drug. The reported data shows that 90% of participants in the BI 1015550 group (9 out of 10 pe...
-
NCT05497284 · results posted 18 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05497284) enrolled 46 people in total — 23 received a treatment called LTP001 (at a 6mg dose) and 23 received a placebo (a dummy treatment with no active ingredient). The trial was looking at changes in lung function over a treatment period, primarily by measuring something called Forced Vital Capacity (FVC) — which is simply the total amount of air a person can breathe out in one go — expressed as a percentage compared to what would be expected for someone of a similar age, sex, and body size. By the end of the study, 15...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT05321069 · results posted 12 September 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,177 people with idiopathic pulmonary fibrosis (IPF) — a condition where the lungs gradually scar over time. Participants were divided into three groups: 393 received a placebo (dummy pill), 392 received a lower dose of nerandomilast (9 mg twice daily), and 392 received a higher dose (18 mg twice daily). The main thing the trial was measuring was the change in "forced vital capacity" (FVC) — a breathing test that measures how much air a person can breathe out in one go — after 52 weeks. Several other outcomes were al...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04533022 · results posted 23 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04533022) enrolled 52 participants, all of whom received a treatment called C21 at a dose of 100 mg twice daily. Of the 52 who started, 27 completed the trial and 25 did not finish. The trial was measuring unwanted health events (called adverse events) that occurred during the study period, as well as changes in a breathing test called Forced Vital Capacity (FVC) — a measure of how much air a person can breathe out in one breath — and the levels of C21 in participants' blood. The reported data shows that, out of 52 partic...
-
NCT05065190 · results posted 20 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05065190) enrolled 81 people in total — 27 received a placebo (an inactive treatment) and 54 received 150 mg of a medicine called nintedanib. The trial ran for 52 weeks and was primarily measuring how quickly lung capacity — specifically a measure called Forced Vital Capacity (FVC), which is the amount of air a person can forcefully breathe out — changed over that period. The reported data shows that lung capacity declined in both groups over the 52 weeks. In the placebo group, the average annual rate of decline in FVC wa...
-
NCT02496585 · results posted 16 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02496585) involved 34 people in total. Nineteen participants received nintedanib combined with prednisone, and fifteen received a placebo combined with prednisone. The trial was measuring how many people in each group remained free from serious lung flare-ups (called pulmonary exacerbations) — defined as a worsening of symptoms such as cough, breathlessness, or low oxygen levels lasting more than four days, along with new abnormalities visible on a chest scan. The reported data shows that, among those who received ninteda...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04308681 · results posted 24 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04308681) enrolled people with two types of serious lung scarring conditions: idiopathic pulmonary fibrosis (IPF) and progressive fibrosing interstitial lung disease (PF-ILD). Participants were randomly assigned to receive either a placebo (inactive treatment) or one of two doses of the investigational medicine BMS-986278 (30 mg or 60 mg). In the IPF group, 93 people started in each of the placebo and 60 mg arms, and 92 in the 30 mg arm. In the PF-ILD group, 41 started on placebo and 42 each in the two active dose arms. Th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05130970 · results posted 13 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05130970) enrolled 81 people in total — 40 received a medicine called garadacimab and 41 received a placebo (a dummy treatment with no active ingredient). The trial was primarily measuring certain medical events that occurred after participants started taking their assigned treatment, including serious medical events, specific events of special concern (such as unusual bleeding, blood clots, or severe allergic reactions), and whether participants' bodies developed antibodies against the study medicine. The reported data s...
-
NCT05870956 · results posted 1 October 2024
According to the results reported on ClinicalTrials.gov, this study looked at 1,798 people in total who had been prescribed a medicine called nintedanib (used for a lung condition called idiopathic pulmonary fibrosis, or IPF — a progressive scarring of the lungs). Participants were grouped based on how consistently they took their medication over time: "High Adherence" (781 people), "Moderate Adherence" (202 people), "High-then-Poor Adherence" (190 people), "Delayed-Poor Adherence" (255 people), and "Early-Poor Adherence" (370 people). The study measured healthcare costs and hospital admission...
-
NCT05875532 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this study enrolled 34,960 participants, all of whom had been diagnosed with a type of scarring lung disease (interstitial lung disease, or ILD) other than the most common form known as IPF. The study was observational, meaning researchers looked back at existing medical records rather than testing a new treatment. The main goal was to track how likely these patients were to have their lung disease worsen — described as "progression to pulmonary fibrosing ILD" — over a period of up to two years after their diagnosis. The reported data s...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT03955146 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03955146) looked at a drug called pamrevlumab compared to a placebo (an inactive treatment) in people with idiopathic pulmonary fibrosis (IPF) — a condition where the lungs gradually scar and stiffen over time. The main thing the trial measured was how much lung capacity changed over 48 weeks, using a breathing test called FVC (Forced Vital Capacity), which measures how much air a person can forcefully breathe out. The trial included two groups: a main study group of 356 people (181 received pamrevlumab, 175 received place...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04419558 · results posted 12 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04419558) enrolled 184 people in the pamrevlumab group and 188 in the placebo group for a 48-week double-blind period, followed by an open-label extension phase of another 48 weeks. The trial was measuring things related to idiopathic pulmonary fibrosis (IPF) — a condition that causes scarring in the lungs. The main thing researchers were tracking was a breathing test called forced vital capacity (FVC), which measures how much air a person can forcibly breathe out. They also tracked how long it took for the disease to prog...
-
NCT03710824 · results posted 31 July 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 180 people who had been diagnosed with idiopathic pulmonary fibrosis (IPF) — a condition where the lungs progressively scar over time. All participants received the medication nintedanib. The trial was measuring several things over a follow-up period, including quality of life, breathlessness, cough, anxiety, how consistently participants took their medication, and how many were using long-term oxygen. Of the 180 who started, 149 completed the study and 31 did not. The reported data shows the following across the mea...
-
NCT03832946 · results posted 22 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03832946) compared an inhaled investigational medicine called GB0139 (taken as a 3 mg once-daily dose) against a placebo (a dummy treatment with no active ingredient) in people with a lung condition called idiopathic pulmonary fibrosis (IPF). A total of 102 people were assigned to the GB0139 group and 70 to the placebo group. The trial's main goal was to measure how quickly lung function — specifically a breathing test result called Forced Vital Capacity (FVC), which measures the amount of air a person can breathe out — ch...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04594707 · results posted 16 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04594707) involved 117 participants across three groups. Twenty-one people were in Cohort A, who received a medicine called zinpentraxin alfa from the start. The remaining 96 participants were split into two groups in Cohort B: 49 who had previously received a placebo (a dummy treatment) and 47 who had previously received zinpentraxin alfa. The trial was measuring things like unwanted medical events (called adverse events), reactions during the medicine drip (infusion-related reactions), and changes over time in lung funct...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04396756 · results posted 30 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04396756) tested a drug called PLN-74809 across four parts (A, B, C, and D), using different doses: 40 mg, 80 mg, 160 mg, and 320 mg. In total, 120 people took part — 1 person in Part A (40 mg), 22 in Part B (40 mg), 23 in Part C (80 mg), 22 in Part C (160 mg), 21 in Part D (320 mg), and 31 who received a placebo (a dummy treatment with no active ingredient). The trial's primary focus was on tracking "treatment-emergent adverse events" — that is, any unwanted medical occurrences that happened after participants started tak...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05022784 · results posted 19 April 2024
According to the results reported on ClinicalTrials.gov, this study enrolled 1,798 people who had been diagnosed with idiopathic pulmonary fibrosis (a scarring lung condition) and had started taking a medicine called nintedanib. All 1,798 participants completed the study. The main thing the trial was looking at was how consistently patients took their nintedanib over 12 months — specifically, whether people kept filling their prescriptions regularly over time, and whether different patterns of medicine-taking could be identified among the group. The reported data shows that researchers identi...
-
NCT04552899 · results posted 18 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04552899) enrolled 331 people in the zinpentraxin alfa group and 333 people in the placebo group — a total of 664 participants. The trial was measuring changes in lung function and physical ability over time in people with a serious lung condition. The main thing being tracked was a breathing test called Forced Vital Capacity (FVC), which measures how much air a person can breathe out. A smaller number (a bigger drop) means lung function has declined more. The reported data shows that, on average, lung capacity (FVC) fell...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04525547 · results posted 12 March 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04525547) enrolled 70 participants, all of whom received the treatment being studied — a medication called Ofev (nintedanib). Of those 70 people, 65 completed the trial and 5 did not. The trial was measuring two main things: how many participants experienced adverse events (unwanted health events recorded during the study), and how a lung function measurement called Forced Vital Capacity (FVC) changed over time. FVC is simply a measure of how much air a person can forcefully breathe out in one go, recorded in millilitres (...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT03313180 · results posted 20 February 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03313180) enrolled 444 participants, all of whom received a medicine called nintedanib. The trial was a single-group study, meaning everyone received the same treatment with no comparison group. The main thing the trial set out to measure was how many participants experienced any unwanted or unexpected health event (called an "adverse event") during the course of the study. Of the 444 people who started, 265 completed the trial, while 179 did not finish — the reasons for not completing were not detailed in the data provide...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03641742 · results posted 18 November 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03641742) involved two groups of participants: 27 people who had already been diagnosed with a familial form of interstitial lung disease (a condition where lung tissue becomes damaged or scarred) — referred to as "proband" participants — and 98 people considered "at-risk" because of a family connection to someone with the condition. All 125 participants who started the trial completed it, with no drop-outs recorded. The trial was looking at whether certain lung changes, called interstitial lung abnormalities (ILAs), could...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03727802 · results posted 23 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03727802) tested a medicine called TRK-250 across two parts (Part A and Part B). In Part A, small groups of three to four participants each received one of four different doses of TRK-250 (2 mg, 10 mg, 30 mg, or 60 mg), while four participants received a placebo (a dummy treatment with no active ingredient). In Part B, groups of four participants received one of three doses of TRK-250 (10 mg, 30 mg, or 60 mg), and six participants received a placebo. In total, 34 people started the trial, and 32 completed it — one person i...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 71 reported results for Interstitial Lung Disease
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a very large amount of public research funding has been directed toward Interstitial Lung Disease, which signals that this condition has attracted serious scientific attention from one of the world's largest medical research bodies. However, the direction of that funding has been falling year on year, meaning the level of investment is declining rather than growing....
See the full Interstitial Lung Disease page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.